Michael A Pleiss

This inventor holds 86 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Leukocyte Adhesion Inhibitors (CPC class C07D-). Top assignees: Elan Pharmaceuticals, Inc., Wyeth, Ingenium Pharmaceuticals Gmbh. Active years: 1999-2020.

USPTO Granted Patents = 86 (Patent Applications = 14)

% Patents Active = 31.4

CIPO Patents = 2 (Patent Applications = 18)

EPO Patents = 10 (Patent Applications = 9)

Average Co-Inventor Count = 6.9

ph-index = 15

Forward Citations = 646(Granted Patents)

Forward Citations (Not Self Cited) = 534(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Fremont, CA (US) (1999)
Sunnyvale, CA (US) (2001 - 2020)

Company Filing History:

47 out of 202

Elan Pharmaceuticals, Inc.

Ingenium Pharmaceuticals Gmbh

patents

4. 2 out of 35

Athena Neurosciences, Inc.

patents

5. 2 out of 4,508

Eli Lilly and Company

patents

6. 2 out of 15,977

University of California

The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone

patents

9. 1 out of 1

The J. David Gladstone Institutes, a Testimentary Trust Established Under the Will of J. David Gladstone

patent

10. 26 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2020

Loading Chart...

Areas of Expertise:

Leukocyte Adhesion

Protein Kinase Inhibitors

Benzoxazine Compounds

VLA-4 Antagonists

Amino Acid Derivatives

Bradykinin Antagonists

Polyethylene Glycol Conjugates

Multimeric Antagonists

Dipeptide Compounds

Fused Ring Compounds

Pyrimidine Derivatives

Sulfonyl Compounds

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10611741 - Substituted benzoxazine and related compounds (2020-04-07),

2. 10087151 - Substituted benzoxazine and related compounds (2018-10-02),

3. 9376423 - PKC-epsilon inhibitors (2016-06-28),

4. 8841315 - Inhibitors of protein kinases (2014-09-23),

5. 8785648 - PKC-epsilon inhibitors (2014-07-22),

6. 8716296 - Inhibitors of protein kinases (2014-05-06),

7. 8507511 - Inhibitors of protein kinases (2013-08-13),

8. 8507498 - 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases (2013-08-13),

9. 8436007 - Inhibitors of protein kinases (2013-05-07),

10. 8389521 - Inhibitors of protein kinases (2013-03-05),

11. 8263063 - Multimeric VLA-4 antagonists comprising polymer moieties (2012-09-11),

12. 7973044 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-07-05),

13. 7968547 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-06-28),

14. 7794700 - Multimeric VLA-4 antagonists comprising polymer moieties (2010-09-14),

15. 7759382 - Acylated amino acid amidyl pyrazoles and related compounds (2010-07-20),

Title: Exploring the Innovations of Michael A Pleiss

Introduction:

Michael A Pleiss is a prolific inventor based in Sunnyvale, CA (US) known for his significant contributions in the field of chemistry and pharmaceuticals. With an impressive track record of 86 patents to his name, Pleiss continues to make waves with his groundbreaking inventions.

Latest Patents:

Among his latest patents, Michael A Pleiss has introduced innovations in the form of substituted benzoxazine and related compounds. These compounds, along with their derivatives and pharmaceutically acceptable salts, showcase Pleiss's expertise in developing cutting-edge pharmaceutical solutions.

Career Highlights:

Having worked at renowned companies like Elan Pharmaceuticals, Inc., Michael A Pleiss has honed his skills and expertise in the pharmaceutical industry. His innovative approach to research and development has led to the creation of novel compounds that have the potential to revolutionize the field of medicine.

Collaborations:

Throughout his career, Michael A Pleiss has collaborated with esteemed professionals such as Eugene D Thorsett and Andrei William Konradi. These collaborations have not only enriched Pleiss's work but have also resulted in the development of innovative solutions that have garnered attention within the industry.

Conclusion:

In conclusion, Michael A Pleiss stands as a prominent figure in the world of inventions and patents, with a remarkable portfolio of 86 patents to his credit. His dedication to innovation and his relentless pursuit of excellence continue to inspire others in the field. Pleiss's contributions are a testament to his ingenuity and commitment to pushing the boundaries of scientific discovery.